Background-The effect of peripheral arterial disease (PAD) on outcomes in patients with chronic heart failure (HF) has not been examined in propensity-matched studies. Methods and Results-Of the 2689 patients with advanced chronic systolic HF in the Beta-Blocker Evaluation of Survival Trial, 441 had a history of PAD. Propensity scores for a history of PAD, calculated for each patient using a multivariable logistic regression model, were used to assemble a matched cohort of 299 and 1015 patients, respectively, with and without PAD who were well balanced on 65 measured baseline characteristics. Cox regression models were used to estimate hazard ratios and 95% CIs for associations between PAD and outcomes during 4.1 years of follow-up. Patients had a mean age of 63Ϯ11 years, 19% were women, and 19% were black. All-cause mortality occurred in 43% and 33% of patients with and without a history of PAD, respectively (hazard ratio when PAD was compared with no history of PAD, 1.40; 95% CI, 1.14 to 1.72; Pϭ0.001). All-cause hospitalization occurred in 75% and 63% of patients with and without PAD, respectively (hazard ratio when PAD was compared with no history of PAD, 1.36; 95% CI, 1.16 to 1.58; PϽ0.0001). PAD-associated hazard ratios for cardiovascular mortality, HF mortality, and HF hospitalization were 1.31 (95% CI, 1.04 to 1.63; Pϭ0.019), 1.40 (95% CI, 0.97 to 2.02; Pϭ0.076), and 1.05 (95% CI, 0.86 to 1.29; Pϭ0.635), respectively. Conclusions-In a well-balanced propensity-matched population of chronic systolic HF patients, a history of PAD was independently associated with increased mortality and hospitalization. (Circ Heart Fail. 2010;3:118-124.) 
P eripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis and predicts adverse cardiovascular outcomes. [1] [2] [3] [4] [5] [6] [7] In a propensity-matched cohort of communitydwelling older adults, we have previously demonstrated that the presence of PAD had an independent association with increased all-cause and cardiovascular mortality. 8 However, the extent to which PAD may be independently associated with outcomes in patients with heart failure (HF) has not been previously examined in a propensity-matched study. In this study, we used a public-use copy of the Beta-Blocker Evaluation of Survival Trial (BEST) 9 dataset to determine the association between a baseline history of PAD and long-term outcomes in a propensity-matched population of advanced chronic systolic HF patients in which those with and without PAD were well balanced in all measured baseline characteristics.
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Methods
Study Data and Patients
The BEST was a multicenter randomized placebo-controlled clinical trial of bucindolol, a ␤-blocker, in advanced systolic HF, methods and results of which have been previously published. 9 Briefly, 2708 patients with advanced systolic HF were enrolled from 90 different sites across the United States and Canada between May 1995 and December 1998. At baseline, patients had a mean duration of 49 months of HF and had a mean left ventricular ejection fraction of 23%. All patients had New York Heart Association class III to IV symptoms, and Ͼ90% of all patients were receiving angiotensinconverting enzyme inhibitors, diuretics, and digitalis.
Study Exposure and Outcomes
The public-use copy of the BEST dataset included 2707 patients (1 patient did not consent to be included in the public-use copy). After excluding 18 patients without data on smoking pack-years, a total of 2689 patients were included in this analysis. Overall, 441 (16%) patients had a history of PAD at baseline. Data on a history of PAD were collected by study investigators and were not centrally adjudicated. Data on sociodemographic, clinical, subclinical, and laboratory variables were collected at baseline. BEST participants were enrolled during a 3-year period and were followed up for a minimum of 18 months and a maximum of 4.5 years. 9 Primary outcomes for this analysis were all-cause mortality and all-cause hospitalization during 4.1 years of follow-up (mean, 2 years; range, 10 days to 4.14 years). Secondary outcomes were mortality due to cardiovascular causes, HF and sudden cardiac death, and hospitalizations due to HF. Values are expressed as n (%) or mean (ϮSD).
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Assembly of a Balanced Cohort of Patients With and Without PAD
As there were significant imbalances in baseline characteristics between patients with and without PAD before matching (Table 1) , we used propensity score matching to assemble a cohort of patients whereby those with and without PAD would be well balanced on all measured baseline covariates. 10 -12 The propensity score for PAD for a patient would be that patient's probability of having PAD given his or her measured baseline characteristics. Propensity scores for PAD were estimated for each of the 2689 patients using a nonparsimonious multivariable logistic regression model. In the model, PAD was the dependent variable, and 65 baseline characteristics displayed in Figure 1 were used as covariates in the model. A number of clinically relevant interactions, such as age by smoking, coronary artery disease (CAD) by smoking, etc, were also were included in initial models but were excluded from the final model due to lack of statistical significance. We used a greedy matching protocol, described in detail elsewhere, to match 1 patient with PAD with up to 4 patients without PAD. Using this approach, we were able to match 299 patients with PAD with 1015 patients without PAD. [13] [14] [15] [16] [17] Because propensity score models are sample-specific adjusters and are not intended to be used for out-of-sample prediction or estimation of coefficients, measures of fitness, and discrimination are not important for the assessment of the model's effectiveness. As such, measures of fitness and discrimination are irrelevant for the assessment of the model's effectiveness. [13] [14] [15] [16] [17] We assessed propensity score models by estimating pre and post-match absolute standardized differences for measured baseline covariates between patients with and without PAD. Absolute standardized differences directly quantify bias in the means (or proportions) of covariates across the groups. They are expressed as a percentage of the pooled standard deviation and are presented in Love plots. [13] [14] [15] [16] [17] An absolute standardized difference of 0% indicates no residual bias, and differences Ͻ10% are considered inconsequential.
Statistical Analysis
Kaplan-Meier and Cox regression analyses were used to determine associations between PAD and outcomes during 4.1 years of followup. Log-minus-log scale survival plots were used to check proportional hazards assumptions. Formal sensitivity analyses were conducted to quantify the degree of a hidden bias that would need to be present to invalidate our conclusions based on significant association between PAD and primary outcomes among matched patients. 18 Subgroup analyses were conducted to determine the homogeneity of association between a history of PAD and all-cause mortality. All statistical tests were 2-tailed with a probability value Ͻ0.05 considered significant. All data analyses were performed using SPSS for Windows version 15 (SPSS, Inc, Chicago, IL). 19
Results
Baseline Characteristics
Matched patients had a mean age of 63 (Ϯ11) years, 19% were women and 19% were black. The significant imbalances in several baseline characteristics before matching and the balances achieved after matching are displayed in Table 1 and Figure 1 . After matching, standardized differences for all measured covariates were Ͻ10% (most were Ͻ5%), suggesting substantial covariate balance across the groups (Figure 1 ).
PAD and Mortality
All-cause mortality occurred in 43% and 33% of patients with and without PAD, respectively (hazard ratio, 1.40; 95% CI, 1.14 to 1.72; Pϭ0.001; Figure 2a and Table 2 ). In the absence of hidden bias, a sign-score test for matched data with censoring provides relatively strong evidence (Pϭ0.035) that patients without PAD clearly outlived those with PAD. A hidden covariate that is a near-perfect predictor of mortality may potentially explain away the association between PAD and all-cause mortality if that would increase the odds of PAD by only 1.3%. No heterogeneity of association between PAD and all-cause mortality was detected in any of the subgroups of patients (Figure 3 ). Associations of PAD with mortality due to cardiovascular causes, HF, and sudden cardiac death are displayed in Table 2 .
PAD and Hospitalization
All-cause hospitalization occurred in 75% and 63% patients with and without PAD, respectively (hazard ratio, 1.36; 95% CI, 1.16 to 1.58; PϽ0.0001; Figure 2b and Table 2 ). In the absence of hidden bias, a sign-score test for matched data with censoring provides strong evidence (Pϭ0.001) that patients without PAD clearly had fewer hospitalizations due to all causes than those with PAD. A hidden covariate that is a near-perfect predictor of hospitalization could potentially explain away our observed association between PAD and all-cause hospitalization, should it increase the odds of PAD by 9.4%. Other pre-and postmatch associations of PAD with hospitalizations are displayed in Table 2 .
Discussion
Findings from this study demonstrate that the prevalence and the burden of CAD was high among patients with systolic HF with a history of PAD, and a history of PAD was associated with increased risk of mortality and hospitalization in these patients. Significant strong bivariate associations of PAD with major natural history end points suggest that the presence of PAD may be used to identify patients with advanced systolic HF who are at an increased risk for poor outcomes. The significant associations of PAD with all-cause mortality 
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and all-cause hospitalization after propensity score matching suggest that the effect of PAD was independent of the 65 measured baseline characteristics that included major cardiovascular risk factors. These findings are important because PAD is common in patients with advanced systolic HF. 20 Strong bivariate associations between PAD and outcomes are likely due to confounding by covariates, such as age, smoking, CAD, and diabetes mellitus, the prevalence of which was higher in those with PAD than in those without PAD. However, associations between PAD and all-cause mortality and all-cause hospitalization persisted despite risk adjustments using multiple approaches including propensity matching. This suggests an intrinsic association between PAD and outcomes in HF that was independent of the measured covariates in our study. However, we are not aware of any mechanistic pathway of a direct and intrinsic effect of PAD on death or hospitalization. One possible explanation is that atherosclerotic diseases in PAD patients are of a greater severity and more advanced or widespread. 1, 21, 22 This is evident from the higher prevalence and burden of CAD and other morbidities in prematch patients with PAD. Although these and other measured confounders were well balanced after matching, it is possible that atherosclerosis progressed at a faster rate during follow-up in patients with PAD than in those without PAD. Findings from our subgroup analysis also suggest a significant PAD-associated increase in mortality among those with CAD. It is also possible that patients with HF with clinical PAD may restrict their physical activity to avoid claudication pain, potentially leading to deconditioning and deterioration of cardiovascular fitness and poor outcomes. 23 Findings from population-based studies suggest that age, smoking, systolic blood pressure, and serum glucose are significantly associated with large vessel PAD. 24 Before matching patients with PAD in our study were older, with a significantly higher prevalence of current smokers and higher pack-years of smoking, higher systolic blood pressure, and higher serum glucose, all indicating the presence of large vessel PAD. Large vessel PAD has been shown to be independently associated with increased mortality. 4 Smoking is one of the strongest predictors for progression of large vessel PAD. 6, 25 Although our matched patients were balanced on pack-years of smoking and prevalence of current smokers, it is possible that the deleterious effects of continued smoking was more profound in the presence of PAD. 26, 27 An examination of the associations between PAD and cause-specific mortalities provide further insight into how PAD may affect mortality in patients with advanced systolic HF. Sudden cardiac death was a major mode of death in our study, accounting for more than half of all deaths. However, PAD apparently was not associated with fatal cardiac arrhythmias underlying sudden deaths. This lack of a statistically significant association between PAD and sudden death suggests that the effect of PAD in HF may be predominantly nonsudden in nature. PAD, however, had significant associations with cardiovascular death, and its association with HF death was of borderline significance. PAD has also been shown to be associated with increased risk of fatal acute myocardial infarction. 5 However, only Ͻ5% of all deaths in our study were due to acute myocardial infarction, which may explain the nonsignificant association between PAD and acute myocardial infarction death. PAD-associated increase in the risk of other cardiovascular mortality highlights its impact on vascular deaths such as those due to stroke. Unfortunately, we had limited data on cause-specific hospitalizations with which to gain insights into the PADassociated increase in all-cause hospitalization in patients with advanced systolic HF. Extrapolating from cause-specific mortality data, it may be suggested that PAD-associated increase in hospitalization was primarily due to cardiovascular causes. However, recent reports have suggested an association between PAD and noncardiovascular morbidities. 28, 29 To the best of our knowledge, this is the first report of an association of PAD with mortality and hospitalization in a propensity-matched population of advanced chronic systolic HF patients. Our findings of increased mortality and morbidity in patients with chronic HF with PAD have important clinical and public health implications. PAD may be a manifestation of more severe and/or advanced systemic atherosclerosis, and thus its presence can be used to identify patients with HF with poorer prognosis. This may be useful as an inexpensive clinical tool in developing nations to riskstratify patients with HF. Importantly, PAD may often be asymptomatic and hence underdiagnosed. It is relatively easy, however, to accurately diagnose the presence and severity of PAD by measures such as the ankle-brachial pressure index. Our findings of independent associations of PAD with poor outcomes highlight the importance of prevention and timely detection of PAD, and aggressive treatment of atherosclerotic risk factors in patients with HF.
Management of PAD in HF is similar to that in the general population with a few exceptions. Current recommendations for management of PAD patients are mainly based on reduction of systemic cardiovascular risk, which include smoking cessation, exercise, treatment of hypertension and diabetes, and the use of antiplatelet agents and statins. 30 Walking and physical training have been shown to improve claudication distance in patients with PAD. 31, 32 Cilostazol, a phosphodiesterase-3 inhibitor approved for use in symptomatic PAD, is contraindicated in HF (a black-box warning). Pentoxifylline, a phosphodiesterase-4 inhibitor, also approved for use in symptomatic PAD, may be safe in HF. 33 However, its efficacy in improving walking distance is very limited. 32 Statins and angiotensin-converting enzyme inhibitors have shown some efficacy for walking distance; however, there is no labeled indication for these drugs. 34 -37 Despite concerns that ␤-blockers may cause or worsen claudication in patients with PAD, these drugs are not contraindicated in these patients. 30 We observed that the effect of PAD on mortality appeared to be heterogeneous between patients receiving and not receiving bucindolol, a ␤-blocker. However, the lack of a significant interaction (Pϭ0.140: Figure 3 ) precludes any inference of heterogeneity. It is possible that the nonsignificant interaction may be due to inadequate power. Considering the potential clinical importance of these findings, future studies with adequate sample sizes are needed to examine the heterogeneity of the effect of PAD on outcomes in patients with HF receiving and not receiving ␤-blockers.
Several limitations of this study must be acknowledged. Findings of this study based on patients with advanced systolic HF enrolled in a clinical trial may not be generalizable to patients with mild-to-moderate systolic HF or diastolic HF. Data on ankle-brachial pressure index were not available and diagnosis of PAD was based on patients' medical history as assessed by study investigators. This may have misclassified some PAD patients and underestimated the true prevalence of PAD. Data were not available on the extent and severity of PAD. It is possible that patients without PAD at baseline may have developed PAD during follow-up, thus resulting in regression dilution bias, which is another potential source of underestimation of the true association between PAD and outcomes. 38 Finally, the findings of our sensitivity analyses suggest that our conclusions were rather sensitive to an unmeasured confounder. However, sensitivity analysis cannot determine whether an unmeasured confounder exists or not. To be a confounder, an unmeasured covariate, in addition to being associated with PAD, would also need to have a near-perfect association with outcomes, without any strong association with any of the 65 measured baseline covariates used in our study, a possibility which seems highly unlikely.
In conclusion, PAD in patients with advanced chronic systolic HF was associated with increased risk of death and hospitalization, which was independent of 65 baseline characteristics including major cardiovascular risk factors. PADassociated poor outcomes in patients with HF are likely nonsudden in nature and likely to be predominantly atherosclerotic in origin. PAD may be useful as an inexpensive screening tool to risk stratify patients with HF.
